非诺贝特通过抑制ANGPTL3通路对糖尿病视网膜病变发挥保护作用
本研究在大鼠糖尿病模型和髙糖处理的人视网膜微血管内皮细胞中,探讨非诺贝特治疗糖尿病视网膜病变与ANGPTL3致病效应之间的关联。结果显示非诺贝特通过抑制ANGPTL3诱导的凋亡和炎症发挥保护作用,为糖尿病视网膜病变治疗提供了新机制。
要点
- 非诺贝特可下调糖尿病视网膜中ANGPTL3、IL-1β、IL-6、Bax、P53、VEGF和整合素αVβ3的表达。
- ANGPTL3 siRNA或整合素αVβ3受体阻断同样下调上述标志物,提示ANGPTL3通路参与病变。
- 非诺贝特通过抑制ANGPTL3诱导的内皮细胞凋亡和炎症发挥视网膜保护作用。
核心结论
- 非诺贝特通过抑制ANGPTL3诱导的凋亡和炎症,对糖尿病视网膜病变发挥保护作用,这是一种新机制。
研究设计与样本
- 糖尿病大鼠和对照大鼠随机接受玻璃体腔注射ANGPTL3 siRNA、重组人ANGPTL3、普通饲料或含非诺贝特饲料8周。
- 人视网膜微血管内皮细胞暴露于正常或髙糖水平,并接受ANGPTL3 siRNA、ANGPTL3 RNA过表达、空白载体、西仑吉肽或非诺贝特处理。
- 采用Western blotting和实时PCR检测大鼠视网膜及HRMECs中ANGPTL3、IL-1、IL-6、Bax、P53、VEGF和整合素αVβ3的表达,TUNEL法检测HRMECs凋亡率。
主要发现
- 在HRMECs髙糖刺激或ANGPTL3过表达后,以及糖尿病视网膜组织中,ANGPTL3、IL-1β、IL-6、Bax、P53、VEGF和整合素αVβ3表达上调。
- 非诺贝特干预、阻断整合素αVβ3受体或ANGPTL3 siRNA干扰后,上述标志物表达下调。
临床怎么用
- 非诺贝特可能通过抑制ANGPTL3通路减轻糖尿病视网膜病变中的内皮细胞凋亡和炎症,为临床用药提供机制依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fenofibrate has been demonstrated to exert a promising therapeutic effect against diabetic retinopathy. Angiopoietin-like 3 (ANGPTL3) has been shown to exert significant pathogenic effects on vascular endothelial cells, which are critically involved in the pathogenesis of diabetic retinopathy. The present study aimed to investigate the link between the therapeutic effects of fenofibrate and the pathogenic effects of ANGPTL3 in diabetic retinopathy. METHODS: Diabetic and control rats were randomly assigned to the following treatments: intravitreal injection with ANGPTL3 small interfering RNA (siRNA), recombinant human (rh)ANGPTL3, fed with normal feeds, or fenofibrate-containing feeds for 8 weeks. Human retinal microvascular endothelial cells (HRMECs) were exposed to normal glucose or high glucose levels with ANGPTL3 siRNA, ANGPTL3 RNA overexpression, blank vector, cilengitide, or fenofibrate treatment. Expression levels of ANGPTL3, IL-1, IL-6, Bax, P53, VEGF, and integrin αVβ3 in the retinas of rats and HRMECs were examined by Western blotting and real-time PCR. The apoptosis rates of HRMECs were examined using a TUNEL apoptosis assay kit. RESULTS: Expression levels of ANGPTL3, IL-1β, IL-6, Bax, P53, VEGF, and integrin αVβ3 were found to be upregulated after high-glucose stimulation or ANGPTL3 overexpression in HRMECs or diabetic retinal tissue. However, expression levels of the above markers were downregulated following fenofibrate intervention, blockage of integrin αVβ3 receptor, or ANGPTL3 siRNA interference. CONCLUSIONS: We identified fenofibrate exerts its protective effects by inhibiting ANGPTL3-induced apoptosis and inflammation in diabetic retinopathy, which is a novel mechanism.
引用
- Wang N, Zou C, Zhao S, et al. Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway. Invest Ophthalmol Vis Sci. 2018. PMID: 30128492. doi:10.1167/iovs.18-24155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。